Global Plasma-derived Factor VIII Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Plasma-derived Factor VIII Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
RECOMBINATE is recombinant Factor VIII, a clotting factor that is deficient in people with hemophilia A.
Plasma-derived Factor VIII report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Plasma-derived Factor VIII market is projected to reach US$ 12950 million in 2029, increasing from US$ 8761 million in 2022, with the CAGR of 5.7% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of hemophilia A and the rising awareness about the importance of early diagnosis and treatment have led to a growing demand for Factor VIII products. The availability of plasma-derived Factor VIII provides an effective treatment option for patients who require clotting factor replacement therapy. Secondly, advancements in manufacturing techniques and purification processes have improved the safety and efficacy of plasma-derived Factor VIII products. Stringent regulatory standards and guidelines for plasma collection and fractionation have instilled confidence among healthcare providers and patients regarding the safety of these products.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Plasma-derived Factor VIII market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Takeda
Octapharma
CSL
Grifols
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Segment by Type
200IU
250IU
Hospital
Pharmacy
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Plasma-derived Factor VIII market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Plasma-derived Factor VIII, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Plasma-derived Factor VIII industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Plasma-derived Factor VIII in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Plasma-derived Factor VIII introduction, etc. Plasma-derived Factor VIII Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Plasma-derived Factor VIII market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Plasma-derived Factor VIII report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Plasma-derived Factor VIII market is projected to reach US$ 12950 million in 2029, increasing from US$ 8761 million in 2022, with the CAGR of 5.7% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of hemophilia A and the rising awareness about the importance of early diagnosis and treatment have led to a growing demand for Factor VIII products. The availability of plasma-derived Factor VIII provides an effective treatment option for patients who require clotting factor replacement therapy. Secondly, advancements in manufacturing techniques and purification processes have improved the safety and efficacy of plasma-derived Factor VIII products. Stringent regulatory standards and guidelines for plasma collection and fractionation have instilled confidence among healthcare providers and patients regarding the safety of these products.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Plasma-derived Factor VIII market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Takeda
Octapharma
CSL
Grifols
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Segment by Type
200IU
250IU
Segment by Application
Hospital
Pharmacy
Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Plasma-derived Factor VIII market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Plasma-derived Factor VIII, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Plasma-derived Factor VIII industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Plasma-derived Factor VIII in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Plasma-derived Factor VIII introduction, etc. Plasma-derived Factor VIII Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Plasma-derived Factor VIII market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices